Novartis is delaying the planned sale of its health food and
slimming and sports nutrition businesses due to a lack of
attractive offers in the current weak economy, the company said
last week.
In February this year Swiss healthcare group Novartis announced its
intention to divest itself of the Health and Functional Food
(H&FF) arm of its Consumer Health sector business in order to
focus on the core pharmaceutical business....
US health science company Forbes Medi-Tech announced this week that
it has exercised its right not to buy back the licensing and
distribution rights to its cholesterol-lowering food ingredient
Reducol from Novartis Consumer Health...
US health science company Forbes Medi-Tech is currently in active
discussions with several major food manufacturers regarding the
commercialisation of its cholesterol-lowering food ingredients.
Swiss pharmaceutical company Novartis, Europe's third-biggest
healthcare group, said on Thursday that net profit for 2001 had
risen by eight per cent to 7.0 billion Swiss francs (€4.7 bn) as
flagship drug sales rose 15 per cent...